Finance Watch: Acrivon Adjusts Expectations To Launch $99.4m IPO

Acrivon Therapeutics, Inc. brought its initial public offering to the US market a week later than originally planned and at different terms than it proposed a week earlier, but the cancer drug developer was able to launch its IPO during a year when tough stock market conditions have made it difficult for many biopharmaceutical companies to go public.

Watertown, MA-based Acrivon priced 7.55 million shares at $12.50 each late on 14 November, grossing $99.4m from the IPO and a concurrent private placement of 400,000 shares with existing shareholder...